Nipah virus (NiV) is a member of the Paramyxoviridae family and the Henipavirus genus. It is a high pathogenicity emerging zoonotic pathogen that causes severe febrile encephalitis in 40% to 75% of human cases. However, there are no approved vaccines or therapeutics for NiV at this time, and only supportive care is available. The current state of NiV diagnosis and treatment highlights the need for additional research and development. Creative Biolabs now provides anti-NiV antibodies and customized antibody services to help with NiV research.
Structure of NiV
NiV is a 40-1900 nm negative sense, single-stranded, nonsegmented, enveloped pleomorphic RNA virus with helical symmetry. It has a single layer of surface protrusions with an average length of 17 nm. An 18.2 kb genome encodes six structural proteins: nucleocapsid (N), phosphoprotein (P), matrix (M), fusion glycoprotein (F), attachment glycoprotein (G), and long polymerase (L), as well as three non-structural proteins encoded by the P gene: V, W, and C protein. The virus ribonucleoprotein is formed when the N, P, and L are attached to the viral RNA (vRNP). The F and G proteins are in charge of the virion's cellular attachment and subsequent host cell entry. The virus M protein is essential in the final stage of virion assembly from the genome and proteins, mediating morphogenesis and budding. P, V, C, and W have been demonstrated to modulate virulence by inhibiting the cellular interferon response.
Fig.1 Structure of NiV. (Singh, et al., 2019)
Laboratory Diagnosis
Because the symptoms of NiV infection are similar to those of other febrile diseases, early detection is critical for containing an outbreak and facilitating appropriate patient care. Cell culture, virus isolation, a serological assay such as an enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, serum neutralization test, electron microscope observation, or real-time polymerase chain reaction are typically used in NiV laboratory tests (RT-PCR).
Creative Biolabs, an antibody expert, now offers NiV antibody products for a variety of applications. We also provide a fully comprehensive suite of secondary antibodies and isotype controls to meet your needs. Based on our antibody platform, we provide customized antibody development services including antibody discovery, engineering, and customized services. If you are interested in our products or services, please feel free to contact us.
Explore our complete catalog of NiV antibodies to start your research.
References
- Singh, R.K.; et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies-a comprehensive review. Veterinary Quarterly. 2019, 39(1): 26-55.
- Skowron, K.; et al. Nipah Virus-Another Threat From the World of Zoonotic Viruses. Frontiers in Microbiology. 2021, 12.
